Weaver Alice N, Lakritz Stephanie, Mandair Divneet, Ulanja Mark B, Bowles Daniel W
Division of Medical Oncology, University of Colorado School of Medicine, Denver, Colorado, USA.
Division of Hematology/Oncology, University of San Francisco California, San Francisco, California, USA.
Head Neck. 2023 May;45(5):1315-1326. doi: 10.1002/hed.27307. Epub 2023 Mar 1.
Salivary gland carcinomas (SGC) are a rare and variable group of head and neck cancers with historically poor response to cytotoxic chemotherapy and immunotherapy in the recurrent, advanced, and metastatic settings. In the last decade, a number of targetable molecular alterations have been identified in SGCs including HER2 upregulation, androgen receptor overexpression, Notch receptor activation, NTRK gene fusions, and RET alterations which have dramatically improved treatment outcomes in this disease. Here, we review the landscape of precision therapy in SGC including current options for systemic management, ongoing clinical trials, and promising future directions.
涎腺癌（SGC）是一组罕见且异质性的头颈部癌症，在复发、晚期和转移情况下，传统上对细胞毒性化疗和免疫治疗反应不佳。在过去十年中，涎腺癌中已发现许多可靶向的分子改变，包括HER2上调、雄激素受体过表达、Notch受体激活、NTRK基因融合和RET改变，这些改变显著改善了该疾病的治疗结果。在此，我们综述涎腺癌精准治疗的现状，包括当前全身治疗的选择、正在进行的临床试验以及有前景的未来方向。
